NCT05919030View on ClinicalTrials.gov

A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
RADIATION

Intensity-modulated radiotherapy (IMRT)

Esophageal primary tumor: 39.6Gy/2.2Gy Bone metastasis: 30Gy/3Gy Lung, liver, brain metastases, metastatic lymph nodes: 45Gy/3Gy

DRUG

Tislelizumab

200 mg IV Q3W

DRUG

Cisplatin

During concurrent radiation therapy: 25 mg/m² IV QW During consolidation therapy: 75 mg/m² IV Q3W

DRUG

Nab paclitaxel

During concurrent radiation therapy: 75 mg/m² IV QW During consolidation therapy: 220 mg/m² IV Q3W

Trial Locations (1)

430060

RECRUITING

Renmin hosptial of Wuhan University, Wuhan

All Listed Sponsors
lead

Renmin Hospital of Wuhan University

OTHER